Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells
Ceyda Tuba Sengel-Turk1, Canan Hascicek2, Filiz Bakar3
1Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara University, 06100, Tandogan, Ankara, Turkey.
AAPS Pharmscitech
|March 24, 2016
Summary
Novel nanoparticles loaded with nimesulide (NMS), a non-steroidal anti-inflammatory drug, show significant anticancer effects against breast cancer cells. Preparation methods influenced nanoparticle effectiveness in delivering NMS for potential cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Pharmacology
Background:
- Non-steroidal anti-inflammatory agents exhibit antineoplastic properties, including pro-apoptotic and antiproliferative effects on cancer cells.
- Nimesulide (NMS), a selective COX-2 inhibitor, is being investigated for its anticancer potential.
- Drug delivery systems are crucial for enhancing the efficacy and targeting of anticancer agents.
Purpose of the Study:
- To develop novel poly(ethyleneglycol)-block-poly(ε-caprolactone) (PEG-b-PCL) nanoparticles encapsulating nimesulide (NMS).
- To evaluate the anticancer activity of NMS-loaded PEG-b-PCL nanoparticles against MCF-7 breast cancer cells.
- To assess the impact of different fabrication techniques on nanoparticle characteristics and anticancer efficacy.
Main Methods:
- PEG-b-PCL nanoparticles encapsulating NMS were fabricated using emulsion-solvent evaporation (high shear homogenization, ultrasonication) and nanoprecipitation.
- Nanoparticles were characterized for entrapment efficiency, size, surface charge, and thermal behavior.
- In vitro drug release, cell viability assays (MCF-7 cells), and apoptosis studies were conducted.
Main Results:
- Spherical nanoparticles with negative surface charges were successfully produced, with average diameters ranging from 148.5 to 307.2 nm.
- All formulations exhibited a biphasic drug release pattern in vitro.
- NMS-loaded nanoparticles demonstrated significant dose-dependent anticancer activity against MCF-7 cells, with preparation method influencing cell proliferation effects.
Conclusions:
- PEG-b-PCL nanoparticles are a promising platform for NMS delivery in breast cancer treatment.
- The fabrication technique significantly impacts the physicochemical properties and in vitro anticancer efficacy of NMS-loaded nanoparticles.
- Further research is warranted to explore the therapeutic potential of these nanoparticles for breast cancer therapy.
